Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 16.76 EUR Market Closed
Market Cap: 490.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Relative Value

The Relative Value of one MEDCL stock under the Base Case scenario is 7.46 EUR. Compared to the current market price of 16.76 EUR, Medincell SA is Overvalued by 56%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MEDCL Relative Value
Base Case
7.46 EUR
Overvaluation 56%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
25
vs Industry
6
Median 3Y
25.1
Median 5Y
32.6
Industry
2.5
Forward
15.1
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-7.8
Industry
21.8
Forward
-46.6
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-11.8
Industry
16.1
vs History
vs Industry
Median 3Y
-10.9
Median 5Y
-14.1
Industry
23.8
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-10.1
Industry
2.1
vs History
28
vs Industry
6
Median 3Y
28.1
Median 5Y
31.5
Industry
2.7
Forward
16.1
vs History
30
vs Industry
3
Median 3Y
36
Median 5Y
46.4
Industry
5.2
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-10.7
Industry
13.5
Forward
111.8
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-9.9
Industry
16.8
Forward
-226.1
vs History
vs Industry
Median 3Y
-10.9
Median 5Y
-12.7
Industry
15.2
vs History
vs Industry
Median 3Y
-10
Median 5Y
-11.9
Industry
19.3
vs History
3
vs Industry
6
Median 3Y
12.9
Median 5Y
14
Industry
1.9

Multiples Across Competitors

MEDCL Competitors Multiples
Medincell SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Medincell SA
PAR:MEDCL
490.7m EUR 53.9 -19.5 -27.4 -25.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.2B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
350.6B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
252B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.4 10.5 15.9
P/S Multiple
Revenue Growth P/S to Growth
FR
Medincell SA
PAR:MEDCL
Average P/S: 382 946.9
53.9
1 051%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
FR
Medincell SA
PAR:MEDCL
Average P/E: 32.3
Negative Multiple: -19.5
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBITDA: 459.5
Negative Multiple: -27.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBIT: 2 011.2
Negative Multiple: -25.1
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Discover More
Back to Top